Laigo Bio, with CMM-PI Madelon Maurice as scientific founder, raises €11.5M seed financing to advance its SureTAC™ targeted protein degradation pipeline Dec 9 Written by Aniek Janssen These proceeds will support the advancement of the SureTAC™ oncology programs toward clinical development, the acceleration of discovery as well as development efforts across three SureTAC™ immunology candidate programs: addressing autoimmune-, inflammatory- indications and graft rejection.See here for more information on Laigo Bio and our other entrepeneurs. Aniek Janssen Previous Previous New paper out from Jooske Monster (Gloerich lab), Caterina Manzato (Schuijers lab) and teams! Next Next Charlotte van Gelder (postdoc Burgering lab) has received funding from ELA international to study the effect of GFAP mutations on brain development
Laigo Bio, with CMM-PI Madelon Maurice as scientific founder, raises €11.5M seed financing to advance its SureTAC™ targeted protein degradation pipeline Dec 9 Written by Aniek Janssen These proceeds will support the advancement of the SureTAC™ oncology programs toward clinical development, the acceleration of discovery as well as development efforts across three SureTAC™ immunology candidate programs: addressing autoimmune-, inflammatory- indications and graft rejection.See here for more information on Laigo Bio and our other entrepeneurs. Aniek Janssen
